Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:767  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 

   Table of Contents     
Year : 2022  |  Volume : 14  |  Issue : 4  |  Page : 129-130
State of the globe: Candida auris-a global healthcare threat

Department of Microbiology, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India

Click here for correspondence address and email

Date of Submission12-Nov-2022
Date of Acceptance18-Nov-2022
Date of Web Publication30-Nov-2022

How to cite this article:
Thakur S. State of the globe: Candida auris-a global healthcare threat. J Global Infect Dis 2022;14:129-30

How to cite this URL:
Thakur S. State of the globe: Candida auris-a global healthcare threat. J Global Infect Dis [serial online] 2022 [cited 2023 Feb 7];14:129-30. Available from:

Candida auris (CA) a dreaded, multidrug-resistant (MDR) pathogen, has emerged as a global threat to health care with a crude in-hospital case-fatality rate of 30%–72%.[1] The name "auris" was given because it was first isolated from the ear canal of a hospitalized patient.[2] CA is considered the first example of a new pathogenic fungus emerging from the global warming.[3] The special ability of CA to adapt through the genetic and epigenetic switches first in the environment and then in an avian host is thought to have led to its establishment as a human pathogen.[3] Once established as a pathogen, CA gets easily transmitted among humans, favored by the conditions of high population density, pollution, increased city temperatures, poor hygiene, and frequent international travel.[3]

First identified in 2009, the Centers for Disease Control and Prevention (CDC) had confirmed the presence of CA in 48 countries on six continents by February 2021.[4] The global spread of CA has become so widespread that CDC has now stopped updating the cases of CA outside of the US.[4] CA infection was made notifiable in the US in 2018 and since then US has recorded 1631 clinical cases of CA and 4616 patients with CA colonization.[4] Colonized humans carry CA on the skin, nares, oropharynx, rectum, groin, and many other body parts. They may be totally asymptomatic but they become the vehicles of transmission of CA causing hospital outbreaks with high mortality (30%–72%) among those having candidemia.[1] CA now forms 5%–30% of all reported candidemias in the hospital settings.[1]

The standard biochemical methods and commercially available tests such as VITEK 2 YST, API 20C, BD Phoenix yeast identification system, and MicroScan have been shown to wrongly report CA as other Candida species such as Candida haemulonii, Candida famata, Candida guilliermondii, Candida lusitaniae, and Candida parapsilosis.[5] The species-level identification of Candida may not be available in most laboratories across the world, making it impossible to correctly identify CA. The species-level identification requires more advanced techniques, such as DNA sequencing matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry (MS), or both.[5]

Ninety percent of the CA isolates were found to be resistant to fluconazole, a drug used as the first-line agent for Candida infections.[6] CA was the first Candida species to be classified as MDR and some strains of CA are even pan-resistant.[6] Overall, 25% and 13% of isolates were MDR and multiazole resistant, respectively.[6] CA has become a global threat owing to its MDR nature and things are complicated further by the fact that CA is very difficult to identify with standard laboratory tests used in microbiology laboratories worldwide leading to its gross underreporting.[7]

Risk factors for CA infections are similar to those for other Candida species that include old age, diabetes, recent surgery, indwelling catheters or medical devices, immunosuppression, neutropenia, chronic kidney disease, broad-spectrum antibiotic, or antifungal drug usage.[2] In addition to candidemia, CA has been reported to cause urinary tract infection, otitis media, wound infections, skin abscesses, myocarditis, meningitis, and osteomyelitis.[1]

CA has distinct virulence mechanisms making it a dangerous pathogen and these include tissue invasion, enzyme secretion, nutrient acquisition, histidine kinase-2 component system, secreted aspartyl proteinases, oligopeptide transporters, mannosyltransfersases, secreted proteases, increased survivability at higher temperatures than other Candida species, ability to form biofilms, unique evasion mechanisms to host immune systems, multidrug efflux, genes, and pathways involved in nutrient acquisition and cell wall modeling.[8]

It is imperative to step up the screening and diagnostic facilities for CA in hospital settings, more so in high-population countries like India. Screening for CA among hospitalized patients is an important step in surveillance of this pathogen. Screening is done using a composite swab of the patient's bilateral axilla and groin.[9] The high index of suspicion and species identification of CA are recommended even for Candida isolates grown from nonsterile sites unlike the common belief that Candida grown from nonsterile sites needs no further identification.[9]

The treatment of CA is indicated only if clinical disease is present. Echinocandin is the first-line therapy for CA infection. If unresponsive to this treatment, a combination of echinocandin and liposomal amphotericin B has better efficacy due to their synergistic actions.[7] The high effectiveness of 1% sodium hypochlorite against CA makes it a potential method for reducing CA transmission in nosocomial settings.[10]

In the absence of the more expensive diagnostic facilities such as MALDI-TOF or MS in low- and middle-income countries physicians must suspect CA in the following settings:[7]

  1. If the patient is from an intensive care unit or high-dependency area
  2. In patients transferred from other hospitals after a long stay
  3. Patients who have undergone multiple interventions
  4. Candida isolates that are resistant to fluconazole
  5. Patients with prior antifungal exposure
  6. Whenever a commercial system reports: C. haemulonii, C. famata, C. guilliermondii, C. lusitaniae, C. parapsilosis, Rhodotorula glutinis, Candida sake, and Saccharomyces cerevisiae.

The health-care sector must watch for comorbidities, and care and devise long-term policies that facilitate patient-specific care to curb the global menace of CA. Strengthening of microbiological identification capabilities and epidemiological surveillance, treatment, prevention, and containment strategies, combined with better awareness about CA among physicians, microbiologists, and health-care workers are indispensable to limit the further spreading of CA. The breeding grounds and risk factors of Candida transmission are present in hospitals so it is crucial to highlight and recognize the possibility of CA outbreaks among these patients.

   References Top

Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care 2018;6:69.  Back to cited text no. 1
Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog 2020;16:e1008921.  Back to cited text no. 2
Casadevall A, Kontoyiannis DP, Robert V. On the emergence of Candida auris: Climate change, azoles, swamps, and birds. mBio 2019;10:e01397-19.  Back to cited text no. 3
Tracking Candida auris | Candida auris | Fungal Diseases | CDC; 2022. Available from: [Last accessed on 2022 Nov 09].  Back to cited text no. 4
Identification of Candida auris | Candida auris | Fungal Diseases | CDC; 2020. Available from: [Last accessed on 2022 Nov 09].  Back to cited text no. 5
Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother 2018;73:891-9.  Back to cited text no. 6
Guidelines | Indian Council of Medical Research | Government of India. Available from: [Last accessed on 2022 Nov 09].  Back to cited text no. 7
Chatterjee S, Alampalli SV, Nageshan RK, Chettiar ST, Joshi S, Tatu US. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics 2015;16:686.  Back to cited text no. 8
Screening for Candida auris Colonization | Candida auris | Fungal Diseases | CDC. 2020. Available from: [Last accessed on 2022 Nov 08].  Back to cited text no. 9
Watkins RR, Gowen R, Lionakis MS, Ghannoum M. Update on the Pathogenesis, Virulence, and Treatment of Candida auris. Pathog Immun 2022;7:46-65.  Back to cited text no. 10

Correspondence Address:
Dr. Suman Thakur
Department of Microbiology, Indira Gandhi Medical College, Shimla, Himachal Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jgid.jgid_215_22

Rights and Permissions


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded273    
    Comments [Add]    

Recommend this journal

Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice | Contact Us
2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008